GlassScriptPhysician profile
Amy Lane
NPI 1932717816
$2,793.76
in general payments reported to CMS, 2019-2025
23 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $464 · 2023: $906 · 2024: $741 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,973.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,128.80 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $189.63 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $183.92 | 2024-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $168.15 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $167.08 | 2021-2024 | Myrbetriq, Veozah |
| Pfizer INC. | $152.67 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.87 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $127.27 | 2022-2025 | |
| Esperion Therapeutics, INC. | $88.33 | 2021 | |
| Sumitomo Pharma America, INC. | $78.56 | 2024 | Gemtesa |
| Exact Sciences Corporation | $77.29 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $57.38 | 2022-2025 | Mounjaro |
| Janssen Scientific Affairs, LLC | $36.01 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $26.27 | 2024 | Arexvy, Trelegy Ellipta |
| Indivior INC. | $25.74 | 2024 | Sublocade |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25.31 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $20.87 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $20.13 | 2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $18.73 | 2025 | Camzyos |
| Vanda Pharmaceuticals INC. | $17.39 | 2022 | |
| Biogen, INC. | $16.41 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.86 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.